Prognia
Drug Database
🇪🇺EU · EMALapsedATC: M05BA06

Ibandronic Acid Sandoz(ibandronic acid)

Breast Neoplasms;Neoplasm Metastasis;Fractures, Bone

Marketing Authorisation Holder: Sandoz GmbH

EMA Authorisation: 26/07/2011

INN: ibandronic acid

Indication

Ibandronic acid Sandoz is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Ibandronic Acid Sandoz — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.